Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Sep 5, 2020
Posted in: Investor updates

Home » Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Sep 5, 2020
Posted in: Investor updates

Imagion Biosystems gives notice that, on 4 September 2020 the Company issued 2,514,666 fully paid ordinary shares (Shares) in the Company as the result of shareholders exercising their options in the Company.

Read the notice.

Quarterly Activity Report – Quarter ending 31 December 2023

January 31, 2024

Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal

[VIDEO] EGM Recording – 13 November 2023

November 14, 2023

https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is

Quarterly Activity Report – Quarter ending 30 September 2023

October 31, 2023

Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Related Articles

Quarterly Activity Report – Quarter ending 31 December 2023

[VIDEO] EGM Recording – 13 November 2023

Quarterly Activity Report – Quarter ending 30 September 2023

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list